SCHEMBL5075147

SCHEMBL5075147

CCCCn1c(CN(CCC(C)C)Cc2ccc(N(C)C)cc2)cnc1-c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.39
ALDH1A1 P00352 5/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 2/20 0.38
TP53 P04637 1/20 0.38
GAA P10253 1/20 0.38
MCL1 Q07820 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HSD11B1 P28845 2/20 0.36
TLR7 Q9NYK1 1/20 0.35
C5AR1 P21730 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33
PSMD14 O00487 1/20 0.33
KDM4E B2RXH2 2/20 0.32
CYP3A4 P08684 2/20 0.32
HPGD P15428 2/20 0.32
NPC1 O15118 1/20 0.32
CYP1A2 P05177 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5136223 0.89 MEN1 (0.39) ALDH1A1MAPTMAPK1TP53GAA
SCHEMBL5135816 0.89 TSHR (0.44) TSHRALDH1A1MAPTMAPK1TP53
SCHEMBL1912760 0.83 TSHR (0.48) TSHRALDH1A1HSD11B1C5AR1KDM4E
SCHEMBL5136725 0.82 C5AR1 (0.55) TSHRALDH1A1TP53L3MBTL1C5AR1
SCHEMBL5137499 0.82 HSD11B1 (0.36) TSHRALDH1A1MAPK1HSD11B1MEN1
SCHEMBL5072278 0.81 TSHR (0.51) TSHRALDH1A1MAPK1HSD11B1C5AR1
SCHEMBL5135900 0.81 TLR7 (0.42) TSHRALDH1A1MAPTMAPK1TP53
SCHEMBL5137056 0.81 MEN1 (0.40) TSHRALDH1A1MAPTTP53TLR7
SCHEMBL5075074 0.81 TSHR (0.46) TSHRHSD11B1KMT2ANR1H3PDE4B
SCHEMBL14415668 0.80 MEN1 (0.38) TSHRALDH1A1MAPTMAPK1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed